Key Performance Parameters For High Capacity Protein A Resin

Currently more than 70 biosimilar mAbs (monoclonal antibodies) are under development and multiple originator mAbs are going off-patent in the next 3-4 years. Protein A affinity media remains the most important workhorse for the purification of monoclonal antibodies. Protein A media has a high impact on both development and manufacturing cost, in particular during early stage clinical phases. This application note summarizes the key performance parameters for our high capacity protein A resin, Amsphere A3, for 6 biosimilar molecules of which 5 are mAbs and 1 is a Fc-fusion protein.